[#item_full_content] “As DEA rescheduling cases merge and federal hemp litigation moves to the D.C. Circuit, MMJ argues that companies following FDA rules should not be disadvantaged while non-FDA-approved cannabinoid products receive 
Read More
Marijuana Rescheduling or Regulatory Failure? D.C. Appellate Court Will Rule
ByPot Shop News
June 7, 2026